Table of Contents
ACE Inhibitors and ARBs During the COVID-19 Pandemic
How should clinicians navigate clinical uncertainty for patients who are taking angiotensin-converting–enzyme inhibitors or angiotensin-receptor blockers?
Allan S. Brett, MD and David M. Rind, MD reviewing Patel AB and Verma A. JAMA 2020 Mar 24 Gurwitz D. Drug Dev Res 2020 Mar 4 American College of Cardiology. 2020 Mar 17
Chloroquine and hydroxychloroquine in the context of COVID-19
Chloroquine and closely related structural analogs, employed initially for the treatment of malaria, are now gaining worldwide attention due to the rapidly spreading pandemic caused by severe acute respiratory syndrome-coronavirus-2, named coronavirus disease (COVID) of 2019 (COVID-19). Although much of this attention has a mechanistic basis, the hard efficacy data for chloroquine/hydroxychloroquine in the management of the clinical syndrome of COVID-19 have been limited thus far
The available data taken together show that chloroquine/ HCQ appears to have a potential role in the management of the clinical syndrome of the COVID-19. However, the level of preclinical and clinical evidence is not robust and must be backed by a higher level of data. Unfortunately, lack of alternative therapy, high rate of infectiousness and mortality, and the rapidity of spread elevate the nature of public health hazards related to COVID-19. The pandemic has many health and non-health ramifications, including the global recession.